In patients with polycythemia vera uncontrolled with hydroxyurea
PROVIDE THE PATH THAT MAY
LEAD TO MORE CONTROL
INTERVENE WITH JAKAFI
Indications and Usage
Jakafi is indicated for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea .
Important Safety Information
Treatment with Jakafi can cause thrombocytopenia , anemia and neutropenia , which are each dose-related effects . Perform a pretreatment complete blood count ( CBC ) and monitor CBCs every 2 to 4 weeks until doses are stabilized , and then as clinically indicated
Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi . Platelet transfusions may be necessary
Patients developing anemia may require blood transfusions and / or dose modifications of Jakafi
Severe neutropenia ( ANC < 0.5 × 10 9 / L ) was generally reversible by withholding Jakafi until recovery
Jakafi is a registered trademark of Incyte Corporation . © 2016 , Incyte Corporation . All rights reserved . RUX-1819c 05 / 16
Serious bacterial , mycobacterial , fungal and viral infections have occurred . Delay starting Jakafi until active serious infections have resolved . Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly
Tuberculosis ( TB ) infection has been reported . Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly . Prior to initiating Jakafi , evaluate patients for TB risk factors and test those at higher risk for latent infection . Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB . Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
Progressive multifocal leukoencephalopathy ( PML ) has occurred with ruxolitinib treatment for myelofibrosis . If PML is suspected , stop Jakafi and evaluate
Advise patients about early signs and symptoms of herpes zoster and to seek early treatment
Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus ( HBV ) infections . Monitor and treat patients with chronic HBV infection according to clinical guidelines